Abstract
Obesity is associated with increased risk of positive surgical margins and prostate specific antigen (PSA) recurrence among men undergoing radical prostatectomy. To what degree positive margins contribute to poorer outcome is unclear. Thus, we sought to examine the association between body mass index (BMI) and more objective measures of tumor aggressiveness, tumor grade and size. We carried out a retrospective analysis of 2302 patients treated with radical prostatectomy at the Duke Prostate Center from 1988–2007. Tumor volume was calculated by multiplying prostate weight by percent of specimen involved with cancer. Associations between BMI and tumor volume and high-grade disease (Gleason⩾4+3) independent of pre-operative clinical characteristics of age, race, PSA, clinical stage, biopsy Gleason sum, and year of surgery were assessed using linear and logistic regression, respectively. Mean and median BMI among all subjects was 28.1 and 27.6 kg m–2, respectively. Increased BMI was significantly associated with younger age (P<0.001), black race (P<0.001), more recent year of surgery (P<0.001), and positive surgical margins (P<0.001). After adjusting for multiple clinical pre-operative characteristics, higher BMI was associated with a greater percent of the prostate involved with cancer (P=0.003), increased tumor volume (P<0.001), and high-grade disease (P=0.007). Men with a BMI ⩾35 kg m2 had nearly 40% larger mean tumor volumes than normal weight men (5.1 versus 3.7 cc), after adjustment for multiple clinical characteristics. In this study, obese men undergoing radical prostatectomy had higher-grade and larger tumors, providing further evidence that obese men undergoing radical prostatectomy have more aggressive prostate cancers.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Freedland SJ, Grubb KA, Yiu SK, Humphreys EB, Nielsen ME, Mangold LA et al. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. J Urol 2005; 174: 919–922.
Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004; 22: 439–445.
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ . Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625–1638.
Freedland SJ, Grubb KA, Yiu SK, Nielsen ME, Mangold LA, Isaacs WB et al. Obesity and capsular incision at the time of open retropubic radical prostatectomy. J Urol 2005; 174: 1798–1801.
Jayachandran J, Aronson WJ, Terris MK, Presti Jr JC, Amling CL, Kane CJ et al. Obesity and positive surgical margins by anatomic location after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. BJU Int 2008.
Davies BJ, Walsh TJ, Ross PL, Knight SJ, Sadetsky N, Carroll PR et al. Effect of BMI on primary treatment of prostate cancer. Urology 2008; 72: 406–411.
Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008; 300: 173–181.
Wong YN, Mitra N, Hudes G, Localio R, Schwartz JS, Wan F et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006; 296: 2683–2693.
Freedland SJ, Giovannucci E, Platz EA . Are findings from studies of obesity and prostate cancer really in conflict? Cancer Causes Control 2006; 17: 5–9.
Freedland SJ, Sun L, Kane CJ, Presti Jr JC, Terris MK, Amling CL et al. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. BJU Int 2008; 102: 969–974.
Rampersaud EN, Sun L, Moul JW, Madden J, Freedland SJ . Percent tumor involvement and risk of biochemical progression after radical prostatectomy. J Urol 2008; 180: 571–576 discussion 576.
Freedland SJ, Terris MK, Platz EA, Presti Jr JC . Body mass index as a predictor of prostate cancer: development versus detection on biopsy. Urology 2005; 66: 108–113.
Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006; 15: 1977–1983.
Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA et al. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy? J Urol 2007; 177: 102–106; discussion 106.
Hammarsten J, Hogstedt B . Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001; 39: 151–158.
Bray GA . The underlying basis for obesity: relationship to cancer. J Nutr 2002; 132: 3451S–3455S.
Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E et al. Insulin receptor expression by human prostate cancers. Prostate 2009; 69: 33–40.
Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008; 9: 1039–1047.
Hammarsten J, Hogstedt B . Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005; 41: 2887–2895.
Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 2005; 14: 1262–1269.
Chan JM, Gann PH, Giovannucci EL . Role of diet in prostate cancer development and progression. J Clin Oncol 2005; 23: 8152–8160.
Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007; 298: 2275–2280.
Acknowledgements
Supported by the Division of Urologic Surgery and Department of Surgery, Duke University School of Medicine, Department of Defense Prostate Cancer Research Program (SJF and LLB), and the American Urological Association Foundation Astellas Rising Star in Urology Award (SJF). Views and opinions of, and endorsements by the author(s) do not reflect those of the US Army or the Department of Defense.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Freedland, S., Bañez, L., Sun, L. et al. Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer Prostatic Dis 12, 259–263 (2009). https://doi.org/10.1038/pcan.2009.11
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/pcan.2009.11
Keywords
This article is cited by
-
The effect of medical castration on lipid levels in black South African men with prostate cancer
African Journal of Urology (2022)
-
Interactions Between Obesity and One-Carbon Metabolism Genes in Predicting Prostate Cancer Outcomes Among White and Black Patients
Journal of Racial and Ethnic Health Disparities (2022)
-
Trends in cancer mortality among people with vs without diabetes in the USA, 1988–2015
Diabetologia (2020)
-
Performance of prostate cancer recurrence nomograms by obesity status: a retrospective analysis of a radical prostatectomy cohort
BMC Cancer (2018)
-
20 years—A retrospective of prostate cancer and prostatic diseases
Prostate Cancer and Prostatic Diseases (2018)